Safety, Pharmacokinetics, and Efficacy of RO7567132 Alone and with Atezolizumab in Patients with Advanced or Metastatic Solid Tumors

The primary objective of this study is to evaluate the **safety** of RO7567132 as a single agent and in combination with **Atezolizumab** in individuals with advanced and/or metastatic solid tumors. This is clinically relevant as it aims to determine the tolerability and potential adverse effects of the treatment, which is crucial for assessing its viability as a therapeutic option for patients with these types of tumors. Additionally, the study seeks to understand how the body metabolizes and eliminates RO7567132, providing insights into its pharmacokinetics and informing dosage considerations.

The clinical trial involves a total of **36 participants** diagnosed with **advanced and/or metastatic solid tumors**. The study population includes both male and female subjects, with an **age range** spanning from 18 to 64 years. Participants were selected without targeting any vulnerable populations. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective or specific inclusion criteria for the study.

The clinical trial is designed to evaluate the safety, pharmacokinetics, and efficacy of **RO7567132** as a single agent and in combination with **Atezolizumab** in individuals diagnosed with **advanced and/or metastatic solid tumors**. This study is structured as a Phase 1 trial, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The trial is projected to commence recruitment on September 2, 2024, and is anticipated to conclude by June 19, 2029, encompassing a comprehensive duration of approximately five years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be enrolled and randomized into treatment groups. The trial will include multiple follow-up visits to monitor safety, drug metabolism, and therapeutic outcomes. These visits will be scheduled at regular intervals throughout the study period. The end-of-study visit will mark the completion of the participant's involvement, during which final assessments will be conducted to evaluate the overall impact of the treatment.

The expected length of participant involvement will vary depending on individual response and tolerance to the treatment, with provisions for early termination in cases of adverse events, withdrawal of consent, or non-compliance with study protocols. Participants will be closely monitored to ensure adherence to the study requirements and to safeguard their well-being throughout the trial. The study aims to contribute valuable insights into the treatment of advanced and/or metastatic solid tumors, potentially informing future therapeutic strategies.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on September 2, 2024, with an estimated completion date of June 19, 2029. Specific efficacy parameters, endpoints, and methods for measurement and analysis are not detailed in the provided data. The trial will adhere to standard protocols for data collection and analysis, ensuring that any efficacy assessments are conducted using scientifically validated methods appropriate for a Phase 1 trial. The absence of detailed endpoints suggests that the primary focus may be on safety and tolerability, with efficacy being a secondary consideration. The trial will proceed in accordance with regulatory guidelines and ethical standards, ensuring the integrity and reliability of the data collected.